Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 203,748
  • Shares Outstanding, K 72,251
  • Annual Sales, $ 67,430 K
  • Annual Income, $ -165,840 K
  • EBIT $ -162 M
  • EBITDA $ -165 M
  • 60-Month Beta 1.73
  • Price/Sales 7.53
  • Price/Cash Flow N/A
  • Price/Book 0.72

Options Overview Details

View History
  • Implied Volatility 235.68% (-10.81%)
  • Historical Volatility 166.66%
  • IV Percentile 60%
  • IV Rank 22.71%
  • IV High 686.04% on 04/08/25
  • IV Low 103.37% on 01/16/26
  • Expected Move (DTE 16) 0.43 (15.07%)
  • Put/Call Vol Ratio 1.38
  • Today's Volume 19
  • Volume Avg (30-Day) 419
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 4,002
  • Open Int (30-Day) 2,677
  • Expected Range 2.40 to 3.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 6
  • High Estimate -0.31
  • Low Estimate -0.53
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +37.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.33 +112.03%
on 01/05/26
3.95 -28.61%
on 01/12/26
+1.45 (+105.84%)
since 01/02/26
3-Month
1.21 +132.67%
on 11/07/25
3.95 -28.61%
on 01/12/26
+1.38 (+95.83%)
since 11/03/25
52-Week
1.01 +179.21%
on 04/09/25
3.95 -28.61%
on 01/12/26
+1.14 (+67.86%)
since 02/03/25

Most Recent Stories

More News
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor...

ZNTL : 2.82 (+12.35%)
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval Initiation of the...

ZNTL : 2.82 (+12.35%)
Pivotal Cancer Trials Gain Momentum as Regulatory Clarity Emerges

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative...

ONCY : 0.8778 (-9.35%)
ZNTL : 2.82 (+12.35%)
NUVB : 5.90 (+4.80%)
OSTX : 1.4100 (+1.44%)
MAIA : 2.00 (+3.09%)
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval,...

ZNTL : 2.82 (+12.35%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients...

ZNTL : 2.82 (+12.35%)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients...

ZNTL : 2.82 (+12.35%)
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients...

ZNTL : 2.82 (+12.35%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...

ZNTL : 2.82 (+12.35%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...

ZNTL : 2.82 (+12.35%)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...

ZNTL : 2.82 (+12.35%)

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative...

See More

Key Turning Points

3rd Resistance Point 3.33
2nd Resistance Point 3.09
1st Resistance Point 2.95
Last Price 2.82
1st Support Level 2.58
2nd Support Level 2.34
3rd Support Level 2.20

See More

52-Week High 3.95
Fibonacci 61.8% 2.83
Last Price 2.82
Fibonacci 50% 2.48
Fibonacci 38.2% 2.13
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar